Journal
MUSCLE & NERVE
Volume 42, Issue 1, Pages 30-37Publisher
WILEY
DOI: 10.1002/mus.21616
Keywords
gene therapy; heart; laminin; muscle; muscular dystrophy
Categories
Funding
- Muscular Dystrophy Association
- Anna-Greta Crafoord Foundation for Rheumatological Research
- Vetenskapsradet
- Greta and Johan Kock, and Alfred Osterlund Foundations
Ask authors/readers for more resources
Several approaches to treat laminin alpha 2 chain-deficient congenital muscular dystrophy (MDC1A) in mouse models have been undertaken. Most have shown promising results in young animals. However, older animals have only been characterized to some extent. Herein we analyze the lifespan of laminin alpha 2 chain deficient mice with transgenic overexpression of laminin alpha 1 chain. Further outcome measures included internalized myonuclei, heart fibrosis, grip strength, and serum creatine kinase activity. We show that laminin alpha 2-chain-deficient animals that overexpress laminin alpha 1 chain survive to up to 1.5-2 years of age. Furthermore, they displayed improved skeletal and heart muscle morphology, near-normal muscle strength, and normalized creatine kinase levels. Such an improvement of the dystrophic phenotype that persists to old age has not been previously demonstrated in mice. Our findings hold promise with regard to the efficient treatment of MDC1A patients in the future. Muscle Nerve 42: 30-37, 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available